Collectively, data obtained using allografts, orthotopic transplantation and genetically-engineered KRAS-driven lung cancer mouse models clearly demonstrate that transient OSKM expression impairs tumor initiation and progression and results in a significant reduction of the tumor burden. This evidence concerns the gene KRAS and lung cancer.